SCHEMBL7943432

SCHEMBL7943432

Cc1cn2cc(C(=O)Nc3ccc(F)c(CNc4cccnc4N)c3)ncc2n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 9/20 0.54
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ROCK1 Q13464 1/20 0.38
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
BACE2 Q9Y5Z0 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
PDGFRB P09619 1/20 0.37
KDR P35968 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
GRM4 Q14833 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7939705 0.89 BACE1 (0.45) BACE1AURKAAURKBBACE2HDAC3
SCHEMBL12303619 0.88 BACE1 (0.44) BACE1AURKAAURKBBACE2HDAC3
SCHEMBL7945242 0.86 BACE1 (0.64) BACE1ROCK1AURKAAURKBHDAC3
SCHEMBL12303675 0.86 BACE1 (0.50) BACE1SMN1; SMN2NPC1RAB9AROCK1
SCHEMBL7944814 0.85 BACE1 (0.52) BACE1SMN1; SMN2NPC1RAB9AAURKA
SCHEMBL7941880 0.84 SMN1; SMN2 (0.57) BACE1SMN1; SMN2NPC1RAB9ABACE2
SCHEMBL7945292 0.81 BACE1 (0.52) BACE1BACE2
SCHEMBL7943303 0.81 BACE1 (0.52) BACE1BACE2
SCHEMBL7941984 0.81 BACE1 (0.49) BACE1SMN1; SMN2NPC1RAB9AAURKA
SCHEMBL7943356 0.81 BACE1 (0.51) BACE1SMN1; SMN2NPC1RAB9AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885SMN1; SMN2 576/4885NPC1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.